Iambic Therapeutics filed for a U.S. IPO on Sept. 21, 2026, aiming to list on Nasdaq under the ticker IAM.
The AI-driven oncology biotech says it will use IPO proceeds to advance three cancer programs, led by IAM1363, with IAM217 and IAM-C1 also in development.
The company’s pitch is being bolstered by a string of Big Pharma collaborations, including a fresh multi-year AbbVie partnership announced the same day as the filing.
Earlier partnerships include Takeda’s multiyear deal worth up to $1.7 billion, plus agreements or collaborations with Lundbeck, Revolution Medicines, Jazz Pharmaceuticals, Bayer, and others.
Iambic is also backed by major investors including Nvidia and Qatar Investment Authority, and has raised about $461.8 million to date.
Sources:
Iambic files for IPO after string of Big Pharma AI partnerships
Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on
Iambic Therapeutics Files for U.S. IPO
Iambic files IPO after signing up AbbVie as new partner
Iambic maintains momentum from Big Pharma collabs with ...
Nvidia-Backed Iambic Therapeutics Files for Nasdaq IPO as 'IAM'
QIA撐腰，Iambic申請那斯達克IPO，累計募資近4.62億美元
Iambic Therapeutics Files for Nasdaq IPO as AI-Driven ...
IAM IPO News - Small molecule biotech Iambic Therapeutics ...
Nvidia-Backed Iambic Therapeutics Files for US IPO
Iambic Therapeutics files for IPO to fund cancer drugs By Investing.com
Nvidia-Backed AI Drug Discovery Company Iambic ...
Iambic Therapeutics Files for Nasdaq IPO to Fund Three ...
Iambic Therapeutics files for Nasdaq IPO to fund cancer drug development